Keytruda Qlex (pembrolizumab / berahyaluronidase alfa-pmph)
Merck · PD-1 Immune Checkpoint Inhibitor (Subcutaneous Formulation)
What is Keytruda Qlex? Keytruda Qlex is a subcutaneous formulation of pembrolizumab co-formulated with berahyaluronidase alfa-pmph. It provides the same checkpoint inhibition as IV Keytruda but via subcutaneous injection.
About Keytruda Qlex
| Brand Name | Keytruda Qlex |
| Generic / INN | pembrolizumab / berahyaluronidase alfa-pmph |
| Drug Class | PD-1 Immune Checkpoint Inhibitor (Subcutaneous Formulation) |
| Manufacturer | Merck |
| Administration | Subcutaneous injection |
| FDA Approval | 2025 |
| Presentation | Keytruda Qlex contains pembrolizumab and berahyaluronidase alfa-pmph in a single-dose vial for subcutaneous administration. |
FDA-Approved Uses for Keytruda Qlex
The following indications are based on FDA approval as of the last review date. Your oncologist will determine appropriate use based on your specific cancer type, stage, biomarker status, and overall treatment plan.
- All FDA-approved indications for pembrolizumab where subcutaneous administration is appropriate
How Does Keytruda Qlex Work?
Pembrolizumab blocks the PD-1 receptor on T cells, restoring anti-tumor immune response. Berahyaluronidase alfa-pmph enables subcutaneous delivery by temporarily depolymerizing hyaluronan in subcutaneous tissue, facilitating absorption of the large protein molecule.
Dosage & Administration
The subcutaneous dose equivalent (determined per FDA approval). The treating oncologist determines frequency based on indication. Administration time is significantly shorter than IV infusion.
Dosing for oncology medications is individualized by the treating oncologist or oncology pharmacist. Do not adjust dosing without consulting your healthcare team. The information on this page is educational only and does not replace the official prescribing information or your provider's guidance.
Warnings, Precautions & Side Effects
General Warning
Immune-mediated adverse reactions apply identically to IV pembrolizumab. Local injection site reactions. Embryo-fetal toxicity.
- Immune-mediated pneumonitis
- Immune-mediated colitis
- Immune-mediated hepatitis
- Immune-mediated endocrinopathies
- Embryo-fetal toxicity
Common Side Effects
- Injection site reactions
- Fatigue
- Musculoskeletal pain
- Rash
- Nausea
- Diarrhea
This is not a complete list. Report any new or worsening symptoms to your oncologist or healthcare provider promptly.
Storage & Handling
Refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze.
Oncology medications require careful handling. BiologicHealthPlus provides cold-chain specialty delivery with temperature monitoring for medications that require refrigeration. Do not use the medication if the storage chain has been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Keytruda Qlex is a specialty oncology medication covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage varies by plan, indication, and formulary tier. BiologicHealthPlus verifies benefits at no cost to patients.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Keytruda Qlex. Our team handles the full prior authorization process — submitting clinical documentation, peer-to-peer reviews when needed, and appeals — at no cost to patients or providers.
🏥 Medicare & Medicaid
Medicare coverage for oncology medications depends on route of administration. Intravenous oncology medications are typically covered under Medicare Part B (medical benefit) when administered in a clinical setting. Subcutaneous formulations may be covered under Part B or Part D depending on administration circumstances. Medicaid coverage varies by state.
🆓 Patient Assistance Programs
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. BiologicHealthPlus can assess your eligibility and help with the application process. Contact our team for a confidential eligibility review.
Prior Authorization Guide Patient Assistance Programs Insurance & Savings Medication Costs
Frequently Asked Questions About Keytruda Qlex
Keytruda Qlex is a subcutaneous formulation of pembrolizumab (Keytruda) co-formulated with berahyaluronidase alfa-pmph, manufactured by Merck. It enables delivery of pembrolizumab via subcutaneous injection rather than IV infusion.
Both products contain pembrolizumab. The key difference is the route of administration: Keytruda is given intravenously, while Keytruda Qlex is injected subcutaneously, typically requiring far less clinic time.
Coverage is plan-dependent. As a newer formulation, prior authorization requirements apply. BiologicHealthPlus can perform a free benefits verification.
Keytruda Qlex is approved for the same indications as IV Keytruda where subcutaneous administration is appropriate. Consult the current FDA prescribing information for the specific approved indications.
Related Medications & Conditions
Related Medications
Keytruda · Tecentriq Hybreza · Tecentriq · Atezolizumab
Related Conditions
Non-small cell lung cancer · Melanoma · Urothelial carcinoma